Oleksandr Dziublyk

Oleksandr Dziublyk

Auto-generated profile, based on publicly available information

Oleksandr Dziublyk

Yanovsky National Institute of Phthisiology and Pulmonology, National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Ukrainian Pulmonology Journal
Verified
Journal Article
Open access
IDI. V. Dziublyk
I. V. Dziublyk
OTO. P. Trokhimenko
O. P. Trokhimenko
SSSerhii Soloviov
Serhii Soloviov
GGG. L. Gumeniuk
G. L. Gumeniuk
ODO. Ya. Dziublyk
O. Ya. Dziublyk
OYO. K. Yakovenko
O. K. Yakovenko

24 October 2022 in Infusion & Chemotherapy
Verified
Journal Article
Open access
PDF file
JCJ. Chiaravalli
J. Chiaravalli
AVA. Verneuil
A. Verneuil
VOV. Osiichuk
V. Osiichuk
DGD. Golyshkin
D. Golyshkin
ODO.Ya. Dziublyk
O.Ya. Dziublyk
ODO.S. Denysov
O.S. Denysov
BACKGROUND. The SARS-CoV-2 pandemic has a significant impact on the global health care system, so effective treatments for coronavirus disease (COVID-19) are urgently needed. Nowadays, drug repurposing is widely considered for COVID-19 therapy; significant attention is paid to inhibitors of transmembrane serine proteases (TMPRSS2), which ensure the penetration of SARS-CoV-2 into the human cells and contribute to their infection. ε-aminocaproic acid (ACA), which has been used worldwide for many years to correct blood loss as a fibrinolysis inhibitor, is also known for its ability to block TMPRRS2. It is approved by the Ministry of Health of Ukraine for the treatment of influenza and acute respiratory viral infections. OBJECTIVE. The aim of our study was to evaluate the antiviral effect of ACA in vitro by staining of SARS-CoV-2 viral antigen (spike protein) and by visual scoring of cytopathogenic effect (CPE). RESULTS AND DISCUSSION. Using immunohistochemistry assay it was found that the mean value of EC50 for ACA on Caco-2 cells was 2.5 mg/ml and on Calu-3 cells – 17.3 mg/ml. Using CPE assay it was identified that the mean value of EC50 for ACA on Caco-2 cells was 6.4 mg/ml and on Calu-3 cells – 8.7 mg/ml. Additional analysis was shown that ACA has low cytotoxicity with CC50 values of >50 mg/ml on Caco-2 cells after 24h and 48h incubation and 37,57 and 41,29 mg/ml on Calu-3 cells after 24h and 48h incubation, respectively. Antiviral activity of ACA was detected when using non-toxic concentrations of the drug and did not depend on the time of introduction of ACA (before the introduction of the virus simultaneously with the pathogen after 1-hour incubation). ACA can be recommended for further in vivo studies on laboratory animals.

30 October 2025 in Tuberculosis, Lung Diseases, HIV Infection
Verified
Journal Article
Open access
PDF file
OYO.K. Yakovenko
O.K. Yakovenko
ODO.YA. Dziublyk
O.YA. Dziublyk
YDYaroslav Dziublyk
Yaroslav Dziublyk
EKE.M. Khodosh
E.M. Khodosh
Objective — to develop a radiological screening scale for pulmonary fibrosis to evaluate radiological patterns of pulmonary fibrosis in patients with post-COVID-19 interstitial lung disease and, based on this scale, to improve the diagnosis of pulmonary fibrosis. Materials and methods. The study included patients (n = 257) who had had severe COVID-19 in 2020 and 2021 and who were diagnosed with post-COVID syndrome with post-COVID-19 interstitial lung disease (PC-ILD). Results and discussion. In 40.8 % of cases (n = 105; women 58 %, men 42 %; mean age (62.45 ± 2.01) years), patients were diagnosed with PC-ILD with pulmonary fibrosis according to high-resolution computed tomography (CT) of the lungs performed in inspiratory mode using fine collimation (0.6–1.5 mm) without administration of contrast medium. Patients from this study group (n = 105) underwent interpretation of CT radiological patterns of the lungs based on the developed Radiological Pulmonary Fibrosis Screening Scale for the localisation and identification of radiological patterns.According to a structured and sequential analysis of CT scans of patients with PC-ILD and diagnosed pulmonary fibrosis (n = 105), using the Radiological Screening Scale for Pulmonary Fibrosis, the diagnosis was confirmed only in 11.43 % of cases based on the identified radiological patterns, which may indicate overdiagnosis of pulmonary fibrosis in this pathology. Conclusions. This scale can potentially be used as an additional diagnostic tool by pulmonologists and ra­­diologists to establish a radiological diagnosis of pulmonary fibrosis in PC-ILD and other interstitial lung diseases with pulmonary fibrosis, as well as an algorithm for artificial intelligence programmes for interpreting radiological patterns in interstitial lung diseases; however, the results obtained are preliminary and not yet confirmed.

27 December 2021 in Infusion & Chemotherapy
Verified
Journal Article
Open access
PDF file
YFYu.I. Feshchenko
Yu.I. Feshchenko
MGM.I. Gumeniuk
M.I. Gumeniuk
МLМ.і. Lynnyk
М.і. Lynnyk
ODO.Ya. Dziublyk
O.Ya. Dziublyk
MKM.M. Kuzhko
M.M. Kuzhko
ТSТ.а. Sprynsian
Т.а. Sprynsian
BACKGROUND. The article presents the results of a continuous, cross-sectional, non-interventional, multicenter retrospective epidemiological study, which included cases of 3443 participants. Questionnaires and rapid test for antibodies to SARS-CoV-2 were used to collect data. OBJECTIVE. To determine the relationship between the systematic use of additional drugs for the prevention of COVID-19, including inhaled antiseptics and inhaled antiviral drugs, separately and in combination with other drugs, and the risk of developing of coronavirus disease (COVID-19). RESULTS AND DISCUSSION. 396 participants (11.8 %) took inhaled antiseptics in any period since March 2020, and 410 participants (12.2 %) took inhaled antivirals. A statistically significant protective relationship between episode of COVID-19 when taking inhaled antiseptics and inhaled antiviral drugs (risk ratio 0.901; 95 % confidence interval 0.856-0.948) was determined. CONCLUSIONS. The use of inhaled antiseptics and inhaled antiviral drugs as additional methods of prevention of COVID-19 has shown a statistically significant effect not only on reducing the risk of COVID-19, but different combinations of inhaled antiseptics or inhaled antiviral drugs with other drug groups as additional methods of preventing COVID-19 had a statistically significant protective relationship with the episode of the disease, with the severity of COVID-19 and with the need for hospitalization.

30 September 2024 in Ukrainian Scientific Medical Youth Journal
Verified
Journal Article
Open access
PDF file
NSNatalia Surtaieva
Natalia Surtaieva
OYOleg Yakovenko
Oleg Yakovenko
SSSerhii Soloviov
Serhii Soloviov
VTViktor Trokhymchuk
Viktor Trokhymchuk
MBMykhailo Babenko
Mykhailo Babenko
VYVitaliy Yachnyk
Vitaliy Yachnyk
The treatment of COVID-19 remains a challenging issue worldwide due to the huge economic losses to society as a result of the disease's widespread prevalence, peculiarities of its course and complications of its development. The purpose of the work was comparative analysis of the effectiveness of new treatment regimens for outpatients with mild COVID-19. 64 medical charts of outpatient diseases with a mild course of COVID-19 were studied. Depending on the treatment regimen used, all patients were divided into two groups that received inhaled ACEs or antiviral therapy with the combination drug nortrelvir/ritonavir. The efficacy of each pharmacotherapeutic alternative would be determined on the basis of retrospective data for the timeframe of normalisation of clinical and laboratory parameters. A rule was established that the set of all clinical and laboratory parameters in the normal range is considered as a clinical endpoint. It was found that the use of ACC treats the disease until the rapid disappearance of clinical symptoms, especially in the first treatment, which works on its rapid therapeutic effect in the initial stages. Nirmatrelvir/ritonavir has also been shown to be effective in reducing symptoms, but its effect is incremental, reaching full relief slightly later than in ACC. Modeling of the dynamics of reaching the clinical point of elimination of all clinical symptoms indicates a pharmacoeconomic advantage of the use of ACC over nirmatrelvir/ritonavir, if the additional costs of treatment do not exceed the cost of three days of treatment.